Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IRWD Ironwood Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: IRWD
Price (delayed)
$0.7172
Market cap
$116.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.2
Enterprise value
$606.66M
Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the
Highlights
The EPS has surged by 97% year-on-year
The net income has soared by 97% YoY
The quick ratio has declined by 30% since the previous quarter
IRWD's revenue is down by 23% YoY and by 10% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.ironwoodpharma.com
Key stats
What are the main financial stats of IRWD
Market
Valuations
Earnings
Shares outstanding
161.82M
Market cap
$116.06M
Enterprise value
$606.66M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.36
EV/EBIT
10.49
EV/EBITDA
10.07
EV/Sales
1.91
Revenue
$317.68M
Gross profit
$317.68M
Operating income
$53M
Net income
-$32.34M
EBIT
$57.84M
EBITDA
$60.23M
Free cash flow
$78.41M
Per share
Balance sheet
Liquidity
EPS
-$0.2
EPS diluted
-$0.2
Free cash flow per share
$0.49
Book value per share
-$2.06
Revenue per share
$1.97
TBVPS
$2.02
Total assets
$327.21M
Total liabilities
$661.27M
Debt
$599.08M
Equity
-$334.05M
Working capital
$112.48M
Debt to equity
-1.79
Current ratio
3.34
Quick ratio
3.08
Net debt/EBITDA
8.15
Margins
Efficiency
Dividend
EBITDA margin
19%
Gross margin
100%
Net margin
-10.2%
Operating margin
16.7%
Return on assets
-8.8%
Return on equity
N/A
Return on invested capital
6.9%
Return on capital employed
20.7%
Return on sales
18.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IRWD stock price
How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
-1.87%
1 week
6.5%
1 month
19.71%
1 year
-89%
YTD
-83.81%
QTD
-51.21%
Financial performance
How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$317.68M
Gross profit
$317.68M
Operating income
$53M
Net income
-$32.34M
Gross margin
100%
Net margin
-10.2%
IRWD's operating margin has surged by 107% year-on-year but it is down by 37% since the previous quarter
The operating income has soared by 105% YoY but it has decreased by 43% from the previous quarter
The net income has soared by 97% YoY
IRWD's net margin has surged by 96% year-on-year
Price vs fundamentals
How does IRWD's price correlate with its fundamentals
Growth
What is Ironwood Pharmaceuticals's growth rate over time
Valuation
What is Ironwood Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
0.36
EV/EBIT
10.49
EV/EBITDA
10.07
EV/Sales
1.91
The EPS has surged by 97% year-on-year
The company's equity fell by 11% QoQ
IRWD's P/S is 90% below its 5-year quarterly average of 3.7 and 79% below its last 4 quarters average of 1.8
IRWD's revenue is down by 23% YoY and by 10% QoQ
Efficiency
How efficient is Ironwood Pharmaceuticals business performance
The return on sales has surged by 108% year-on-year but it has declined by 35% since the previous quarter
Ironwood Pharmaceuticals's ROIC has soared by 106% YoY but it has decreased by 42% from the previous quarter
Ironwood Pharmaceuticals's return on assets has surged by 96% YoY
Dividends
What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IRWD.
Financial health
How did Ironwood Pharmaceuticals financials performed over time
The total assets is 51% less than the total liabilities
The quick ratio has declined by 30% since the previous quarter
Ironwood Pharmaceuticals's current ratio has decreased by 29% from the previous quarter
The company's debt to equity rose by 14% YoY and by 10% QoQ
IRWD's debt is down by 13% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.